WILMINGTON, Del. / Mar 17, 2023 / Business Wire / Phreesia is pleased to announce that the healthcare marketing industry trade publication MM+M has named Alexandra Beneville, Vice President, Life Sciences Content Strategy, to its Women to Watch class of 2023.
Now in its eighth year, the program honors the industry’s “leaders of tomorrow”—women who have inspired their colleagues and “represent the best of what this industry has to offer,” MM+M editor-in-chief Larry Dobrow said. Beneville was one of just 18 women to receive the distinction in 2023.
“I’m honored to be recognized by MM+M alongside a group of such accomplished women leaders,” Beneville said. “I’m incredibly proud of all that Phreesia’s Life Sciences team has accomplished in the last year and look forward to bringing important health content to more patients in 2023.”
Since joining Phreesia last August, Alex has become an integral part of the company’s leadership team, spearheading the growth and expansion of its Life Sciences content strategy and transforming the Life Sciences group’s structure and operations to support the company’s wider business goals. She is admired by her colleagues as a visionary leader and a champion for diversity and inclusion.
“We are thrilled to see Alex awarded this well-deserved honor,” said David Linetsky, Phreesia’s Senior Vice President, Life Sciences. “In just 8 months with Phreesia, Alex has already had a tremendous impact on our success, and we’re excited for all that’s to come under her guidance and leadership.”
About Phreesia Life Sciences
Phreesia empowers life sciences companies to connect with clinically relevant patients, delivering tailored health content in a one-to-one setting. Our PatientConnect offering identifies and motivates the right patients to initiate meaningful conversations, while our PatientInsights product enables our clients to better understand key patient populations.
Phreesia meets patients where they are, both virtually and in person, and reaches them at multiple touchpoints throughout their healthcare journey.
| Last Trade: | US$23.69 |
| Daily Change: | 0.28 1.20 |
| Daily Volume: | 124,625 |
| Market Cap: | US$1.420B |
September 04, 2025 September 04, 2025 September 02, 2025 May 28, 2025 March 12, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load